Motilal Oswal is bullish on Cadila Health has recommended buy rating on the stock with a target price of Rs 345 in its research report dated May 29, 2019.
Motilal Oswal's research report on Cadila Health
Sales at INR37.3b (our est. INR34.9b) were up 15% YoY, largely led by the addition of the Consumer Wellness business (sales at INR4b v/s INR1.3b YoY). US sales at INR18b were up 9.3% YoY. EM formulation sales grew 7% YoY to INR2b. Animal Health business grew 11% YoY to INR1.3b. India sales were muted, growing 2% YoY to INR9b for the quarter. Gross margin stood at 62.9% and contracted 380bp YoY on high base of past year. EBITDA margin at 21.4%, contracted 540bp YoY, largely due to change in product mix and higher other expenses as % of sales (+130bp YoY). Absolute EBITDA at INR8b (our est. INR7.2b) was down 8% YoY. PAT came in at INR4.6b (our est. INR3.9b), down 24% YoY. In FY19, sales/EBITDA/PAT stood at INR131b/INR30b/INR18.7b up 10%/5%/4% YoY.
Outlook
We value Cadila at a revised P/E multiple of 18x 12M forward earnings to factor increased competition in US generics and gradual downtrend in long term growth rate of domestic formulation industry. Maintain Buy with a revised TP of 345.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
